Idelalisib 150mg Tablets

Idelalisib 150mg Tablets represent a highly specialized class of antineoplastic agents known as kinase inhibitors, specifically designed to target the biological pathways that drive the survival and proliferation of malignant B-cells. The active pharmaceutical ingredient, idelalisib, functions as a potent and selective inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3Kδ).

The PI3K pathway is a critical signal transduction route that regulates various cellular functions, including growth, proliferation, differentiation, motility, and survival. In many B-cell malignancies, the PI3Kδ isoform is hyperactive and plays a central role in signaling through the B-cell receptor (BCR), as well as through CXCR4 and CXCR5 chemokine receptors.

By selectively binding to and inhibiting PI3Kδ, Idelalisib 150mg Tablets effectively cut off these vital signaling cascades. This inhibition results in the induction of apoptosis (programmed cell death) in the cancer cells. Furthermore, a unique pharmacodynamic effect of Idelalisib 150mg Tablets is the inhibition of homing and retention of malignant B-cells in the protective microenvironment of lymphoid tissues (such as lymph nodes and bone marrow). This causes the cancer cells to be mobilized into the peripheral blood, where they are deprived of their survival signals and eventually die. This dual mechanism—direct cytotoxicity and disruption of the tumor microenvironment—makes Idelalisib 150mg Tablets a powerful tool in treating lymphoid malignancies.

Indications / Uses of Idelalisib 150mg Tablets

Idelalisib 150mg Tablets are indicated for the treatment of adult patients with relapsed or refractory B-cell malignancies who have exhausted other standard therapeutic options. The precise clinical applications include:

• Relapsed Chronic Lymphocytic Leukemia (CLL): Idelalisib 150mg Tablets are prescribed in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to other comorbidities (such as reduced kidney function or other underlying health issues) that make chemotherapy unsuitable.
• Relapsed Follicular Lymphoma (FL): It is indicated as a monotherapy for patients with Follicular Lymphoma who have received at least two prior systemic therapies. In this setting, the drug offers a chemotherapy-free option for patients whose disease has returned or stopped responding to treatment.
• Relapsed Small Lymphocytic Lymphoma (SLL): Similar to FL, Idelalisib 150mg Tablets are used as a monotherapy for patients with SLL who have received at least two prior systemic therapies, providing a targeted approach to control disease progression.
• Management of Lymphadenopathy: By mobilizing tumor cells out of tissues, the medication is particularly effective at rapidly reducing the size of enlarged lymph nodes (lymphadenopathy) and the spleen (splenomegaly) associated with these cancers.

Key Features

• Highly Selective PI3Kδ Inhibition: Unlike pan-PI3K inhibitors that target multiple isoforms (alpha, beta, gamma, delta), Idelalisib 150mg Tablets specifically target the delta isoform, which is predominantly expressed in leukocytes (white blood cells), thereby minimizing off-target effects in other tissues.
• Oral Administration: The medication is formulated as a tablet for oral use, typically taken twice daily. This convenient dosing regimen allows patients to receive potent cancer therapy in a home setting without the need for intravenous infusions.
• Tumor Mobilization: A key feature is the “compartment shift” phenomenon, where lymphocyte counts in the blood initially rise as tumor cells are flushed out of lymph nodes, serving as a marker of drug activity rather than disease progression.
• Synergy with Immunotherapy: When combined with anti-CD20 monoclonal antibodies like rituximab, Idelalisib 150mg Tablets demonstrate enhanced efficacy, leading to deeper and more durable responses in CLL patients.
• Chemotherapy-Free Option: For frail patients or those with multiple relapses, this medication provides a viable therapeutic avenue that avoids the specific toxicities associated with traditional cytotoxic chemotherapy agents.

Storage for Idelalisib 150mg Tablets

To ensure the pharmacological integrity of Idelalisib 150mg Tablets, proper storage practices are mandatory. The medication should be stored at controlled room temperature, specifically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F) to accommodate transport conditions. It is crucial to keep the tablets in the original container to protect them from moisture and humidity, which can degrade the active ingredient. The bottle should be kept tightly closed when not in use. Do not repackage the tablets into pill organizers unless they offer equivalent protection. Store the medication in a secure, dry place, out of the reach and sight of children and pets.

Important Note on Idelalisib 150mg Tablets

Therapy with Idelalisib 150mg Tablets is associated with significant safety risks and requires strict monitoring by a healthcare professional experienced in the use of antineoplastic therapy. The drug carries Boxed Warnings for several severe, immune-mediated adverse reactions.

Hepatotoxicity: Fatal and/or serious liver toxicity occurred in clinical trials. Elevations in liver enzymes (ALT and AST) are common. Monitor liver tests prior to initiation and at least every 2 weeks for the first 3 months of treatment, then as clinically indicated. If significant elevations occur, treatment interruption or dose reduction is required.

Severe Diarrhea or Colitis: Idelalisib 150mg Tablets can cause severe, late-onset diarrhea or colitis (inflammation of the colon), which can lead to dehydration and death. This is often immune-mediated and responds to corticosteroids. Patients should report any changes in bowel habits immediately.

Pneumonitis and Infections: Fatal and serious pneumonitis (lung inflammation) and infections, such as Pneumocystis jirovecii pneumonia (PJP) and Cytomegalovirus (CMV) reactivation, have been reported. Patients are typically placed on PJP prophylaxis (preventative antibiotics) during treatment and monitored for CMV viremia.

Cutaneous Reactions: Severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), can occur.

Women of childbearing potential must use effective contraception during treatment with Idelalisib 150mg Tablets and for at least one month after the last dose, as the drug can cause fetal harm. Do not discontinue the medication abruptly without medical advice, as this may lead to rapid disease progression. Always take the tablet whole; do not chew, crush, or break it.